<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02257021</url>
  </required_header>
  <id_info>
    <org_study_id>1188.7</org_study_id>
    <nct_id>NCT02257021</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interaction Between Tipranavir and BILR 355 BS Plus Ritonavir in Healthy Male Volunteers</brief_title>
  <official_title>Study of Pharmacokinetic Interaction Between Tipranavir and BILR 355 BS Plus Ritonavir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To determine the effect of BILR 355/r on tipranavir/r pharmacokinetics and the effect of
      tipranavir/r on BILR 355 BS pharmacokinetics
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of tipranavir and BILR 355 BS in plasma over one dosing interval (12 hours) at steady state (AUC0-12h,ss)</measure>
    <time_frame>up to 18 days after start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of tipranavir and BILR 355 BS in plasma at steady state over a dosing interval τ (Cmax,ss)</measure>
    <time_frame>up to 18 days after start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance of BILR 355 BS, tipranavir and ritonavir in plasma following extravascular administration at steady state (CL/F,ss)</measure>
    <time_frame>up to 18 days after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum concentration of BILR 355 BS, tipranavir and ritonavir in plasma at steady state (tmax,ss)</measure>
    <time_frame>up to 18 days after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of BILR 355 BS, tipranavir and ritonavir in plasma at steady state (t1/2,ss)</measure>
    <time_frame>up to 18 days after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution of BILR 355 BS, tipranavir and ritonavir during the terminal phase λz at steady state following an extravascular dose (Vz/F,ss)</measure>
    <time_frame>up to 18 days after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of ritonavir in plasma over one dosing interval (12 hours), (AUC0-12h)</measure>
    <time_frame>up to 18 days after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum measured concentration of ritonavir in plasma at steady state over a dosing interval τ (Cmax,ss)</measure>
    <time_frame>up to 18 days after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measured concentration of BILR 355 BS, tipranavir and ritonavir in plasma 12 hours post last dose at steady state (Cp12h,ss)</measure>
    <time_frame>up to 18 days after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically relevant changes in laboratory parameters</measure>
    <time_frame>up to 28 days after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically relevant changes in vital signs (blood pressure, pulse rate)</measure>
    <time_frame>up to 28 days after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically relevant changes in 12-lead ECG</measure>
    <time_frame>up to 14 days after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 7 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tipranavir and high dose of ritonavir plus BILR 355 BS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BILR 355 BS with low dose of ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BILR 355 BS</intervention_name>
    <arm_group_label>Tipranavir and high dose of ritonavir plus BILR 355 BS</arm_group_label>
    <arm_group_label>BILR 355 BS with low dose of ritonavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir</intervention_name>
    <arm_group_label>Tipranavir and high dose of ritonavir plus BILR 355 BS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose of ritonavir</intervention_name>
    <arm_group_label>BILR 355 BS with low dose of ritonavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose of ritonavir</intervention_name>
    <arm_group_label>Tipranavir and high dose of ritonavir plus BILR 355 BS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥19 and &lt;60 years

          -  BMI ≥18.5 and BMI ≤29.9 kg/m2

          -  Ability to give signed and dated written informed consent prior to admission to the
             study in accordance with good clinical practice (GCP) and the local regulations

        Exclusion Criteria:

          -  Current (symptomatic within the last 30 days) and medically relevant gastrointestinal,
             hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal
             disorders

          -  Surgery of gastrointestinal tract (except appendectomy)

          -  Currently active (symptomatic within the last 30 days) diseases of the central nervous
             system (such as epilepsy) or psychiatric disorders or neurological disorders

          -  History of relevant orthostatic hypotension, fainting spells or blackouts

          -  History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          -  Intake of drugs with a long half-life (&gt;24 hours) within one month prior to
             administration of study drug or during the trial (review with clinical monitor if
             questionable)

          -  Use of drugs within 10 days prior to administration or during the trial, which might
             reasonably influence the results of the trial based on the knowledge at the time of
             protocol preparation (review with clinical monitor if questionable)

          -  Participation in another trial with an investigational drug within one month prior to
             administration or during the trial

          -  Current smoker or smoked within the past 30 days

          -  Alcohol (more than 60 g/day) or drug abuse (positive urine test for illicit
             prescription or non-prescription drugs or drugs of abuse)

          -  Recent blood donation (more than 100 mL within 56 days prior to administration or
             during the trial)

          -  Excessive physical activities (within 1 week prior to study drug administration or
             during the trial)

          -  Any laboratory value outside the normal reference range that is of clinical relevance
             at screening, according to the judgment of the investigator

          -  Inability to comply with dietary regimen required by the protocol

          -  Chronic or relevant acute infections

          -  Infected with hepatitis B or hepatitis C viruses (defined as either being hepatitis B
             surface antigen, or hepatitis C antibody positive)

          -  HIV-1 infected as defined by a positive HIV ELISA test
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2014</study_first_submitted>
  <study_first_submitted_qc>October 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2014</study_first_posted>
  <last_update_submitted>October 2, 2014</last_update_submitted>
  <last_update_submitted_qc>October 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

